UPDATE - UBS Initiates Coverage on Ironwood Pharma (IRWD) with a Neutral; Sidelined Heading Into PDUFA
Tweet
Share
E-mailGet Alerts IRWD Hot Sheet
Price: $4.29 +3.62%
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UPDATE - UBS initiates coverage on Ironwood Pharma (Nasdaq: IRWD) with a Neutral. PT $14.
Analyst, Matthew Harrison, said, "We believe Ironwood’s key product, linaclotide, has significant potential for the treatment of irritable bowel syndrome (IBS-C) and chronic constipation (CC). However, with the market implying ~$2B in 2020E sales, we believe expectations are high and we can’t justify higher sales at this
point. Further, while M&A is possible, we believe Forest (NYSE: FRX) (the likely acquirer) will wait to see launch trends before bidding, thus near-term upside is limited and offset by high spending to support a primary care launch and significant capital needs (we estimate $435M over through 2.014E)."
To see more ratings on IRWD, Click Here
Analyst, Matthew Harrison, said, "We believe Ironwood’s key product, linaclotide, has significant potential for the treatment of irritable bowel syndrome (IBS-C) and chronic constipation (CC). However, with the market implying ~$2B in 2020E sales, we believe expectations are high and we can’t justify higher sales at this
point. Further, while M&A is possible, we believe Forest (NYSE: FRX) (the likely acquirer) will wait to see launch trends before bidding, thus near-term upside is limited and offset by high spending to support a primary care launch and significant capital needs (we estimate $435M over through 2.014E)."
To see more ratings on IRWD, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Swarmer invests in Erik Prince-led Vectus Air Defense Systems
- Myriad Uranium completes acquisition of Rush Rare Metals
Create E-mail Alert Related Categories
FDA, Mergers and Acquisitions, New Coverage, RumorsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
